Pediatric bronchiectasis: No longer an orphan disease

Pediatric Pulmonology

Volumn 51, Issue 5, 2016, Pages 450-469

  Goyal, Vikas ^a,b   Grimwood, Keith ^a,c   Marchant, Julie ^a,b   Masters, I Brent ^a,b   Chang, Anne B ^a,d,e  

^a Centre for Childrens Health Research   (Australia)

^b LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^c GOLD COAST HOSPITAL AND HEALTH SERVICE   (Australia)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

children; chronic suppurative lung disease

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; MACROLIDE; ANTIINFECTIVE AGENT;

AIRWAY REMODELING; ASPERGILLUS; BACTERIUM DETECTION; BRONCHIECTASIS; BRONCHOSCOPY; CHILDHOOD DISEASE; CHLAMYDIALES; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFLUENZAE; HUMAN; INCIDENCE; INNATE IMMUNITY; LUNG CLEARANCE; LUNG LAVAGE; LUNG RESECTION; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIAE; PATHOGENESIS; PATIENT EDUCATION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REINFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; THORAX RADIOGRAPHY; VACCINATION; VIRUS DETECTION; BRONCHUS; CHILD; DEVELOPING COUNTRY; PATHOPHYSIOLOGY; RARE DISEASE;

ANTI-BACTERIAL AGENTS; BRONCHI; BRONCHIECTASIS; CHILD; DEVELOPING COUNTRIES; HUMANS; RARE DISEASES;

EID: 84959314096     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23380     Document Type: Review

References (225)

1. Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, Holland AE, O'Mara P, Grimwood K,. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand thoracic society of Australia and New Zealand guidelines. Med J Aust 2015; 202: 21-23.
2. Barker AF, Bardana EJ Jr., Bronchiectasis: update of an orphan disease. Am Rev Respir Dis 1988; 137: 969-978.
3. Chang AB,. Bronchiectasis: so much yet to learn and to do. Paediatr Respir Rev 2011; 12: 89-90.
4. Fall A, Spencer D,. Paediatric bronchiectasis in Europe: what now and where next ? Paediatr Respir Rev 2006; 7: 268-274.
5. Kapur N, Grimwood K, Masters IB, Morris PS, Chang AB,. Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol 2012; 47: 300-307.
6. King PT, Holdsworth SR, Farmer M, Freezer N, Villanueva E, Holmes PW,. Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009; 6: 130-136.
7. Santamaria F, Montella S, Pifferi M, Ragazzo V, De Stefano S, De Paulis N, Maglione M, Boner AL,. A descriptive study of non-cystic fibrosis bronchiectasis in a pediatric population from central and southern Italy. Respiration 2009; 77: 160-165.
8. Callahan CW,. Bronchiectasis: abated or aborted ? Respiration 2005; 72: 225-226.
9. Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL,. Evaluation of the incidence and age distribution of bronchiectasis from the finnish hospital discharge register. Cent Eur J Public Health 1998; 6: 235-237.
10. Twiss J, Metcalfe R, Edwards E, Byrnes C,. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005; 90: 737-740.
11. O'Grady KA, Torzillo PJ, Chang AB,. Hospitalisation of indigenous children in the northern territory for lower respiratory illness in the first year of life. Med J Aust 2010; 192: 586-590.
12. Das L, Kovesi TA,. Bronchiectasis in children from qikiqtani (Baffin) Region, Nunavut, Canada. Ann Am Thorac Soc 2015; 12: 96-100.
13. Singleton R, Morris A, Redding G, Poll J, Holck P, Martinez P, Kruse D, Bulkow LR, Petersen KM, Lewis C,. Bronchiectasis in Alaska native children: causes and clinical courses. Pediatr Pulmonol 2000; 29: 182-187.
14. Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E,. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration 2005; 72: 233-238.
15. Roberts HJ, Hubbard R,. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010; 104: 981-985.
16. Munro KA, Reed PW, Joyce H, Perry D, Twiss J, Byrnes CA, Edwards EA,. Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression ? Pediatr Pulmonol 2011; 46: 131-138.
17. Einsiedel L, Fernandes L, Spelman T, Steinfort D, Gotuzzo E,. Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an indigenous Australian population. Clin Infect Dis 2012; 54: 43-50.
18. Nathan AM, Muthusamy A, Thavagnanam S, Hashim A, de Bruyne J,. Chronic suppurative lung disease in a developing country: impact on child and parent. Pediatr Pulmonol 2014; 49: 435-440.
19. Bastardo CM, Sonnappa S, Stanojevic S, Navarro A, Lopez PM, Jaffe A, Bush A,. Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax 2009; 64: 246-251.
20. Alzeer AH, Al-Mobeirek AF, Al-Otair HA, Elzamzamy UA, Joherjy IA, Shaffi AS,. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest 2008; 133: 468-473.
21. AkalIn F, Koroglu TF, Bakac S, Dagli E,. Effects of childhood bronchiectasis on cardiac functions. Pediatr Int 2003; 45: 169-174.
22. Valery PC, Torzillo PJ, Mulholland K, Boyce NC, Purdie DM, Chang AB,. Hospital-based case-control study of bronchiectasis in indigenous children in central Australia. Pediatr Infect Dis J 2004; 23: 902-908.
23. Guran T, Turan S, Karadag B, Ersu R, Karakoc F, Bereket A, Dagli E,. Bone mineral density in children with non-cystic fibrosis bronchiectasis. Respiration 2008; 75: 432-436.
24. Chung WS, Lin CL, Lin CL, Kao CH,. Bronchiectasis and the risk of cancer: a nationwide retrospective cohort study. Int J Clin Pract 2015; 69: 682-688.
25. Chung WS, Lin CL, Hsu WH, Kao CH,. Increased risk of lung cancer among patients with bronchiectasis: a nationwide cohort study. QJM 2016; 109: 17-25.
26. Brower KS, Del Vecchio MT, Aronoff SC,. The etiologies of non-CF bronchiectasis in childhood: a systematic review of 989 subjects. BMC Pediatr 2014; 14: 299.
27. Li AM, Sonnappa S, Lex C, Wong E, Zacharasiewicz A, Bush A, Jaffe A,. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management ? Eur Respir J 2005; 26: 8-14.
28. Pizzutto SJ, Grimwood K, Bauert P, Schutz KL, Yerkovich ST, Upham JW, Chang AB,. Bronchoscopy contributes to the clinical management of indigenous children newly diagnosed with bronchiectasis. Pediatr Pulmonol 2013; 48: 67-73.
29. Horani A, Brody SL, Ferkol TW,. Picking up speed: advances in the genetics of primary ciliary dyskinesia. Pediatr Res 2014; 75: 158-164.
30. Gould CM, Freeman AF, Olivier KN,. Genetic causes of bronchiectasis. Clin Chest Med 2012; 33: 249-263.
31. Whitwell F,. A study of the pathology and pathogenesis of bronchiectasis. Thorax 1952; 7: 213-239.
32. Gaga M, Bentley AM, Humbert M, Barkans J, O'Brien F, Wathen CG, Kay AB, Durham SR,. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53: 685-691.
33. Regamey N, Ochs M, Hilliard TN, Muhlfeld C, Cornish N, Fleming L, Saglani S, Alton EW, Bush A, Jeffery PK, et al., Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2008; 177: 837-843.
34. Hayward J, Reid ML,. The cartilage of the intrapulmonary bronchi in normal lungs, in bronchiectasis, and in massive collapse. Thorax 1952; 7: 98-110.
35. Liebow AA, Hales MR, Lindskog GE,. Enlargement of the bronchial arteries, and their anastomoses with the pulmonary arteries in bronchiectasis. Am J Pathol 1949; 25: 211-231.
36. Charan N, Baile E, Pare P,. Bronchial vascular congestion and angiogenesis. Eur Respir J 1997; 10: 1173-1180.
37. Polak J, Petrikova J,. Bronchial vascularization in patients with bronchiectasis. Radiol Clin (Basel) 1978; 47: 262-279.
38. Devaraj A, Wells AU, Meister MG, Loebinger MR, Wilson R, Hansell DM,. Pulmonary hypertension in patients with bronchiectasis: prognostic significance of CT signs. Am J Roentgenol 2011; 196: 1300-1304.
39. Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ,. Non-CF bronchiectasis: clinical and HRCT evaluation. Pediatr Pulmonol 2003; 35: 477-483.
40. Cole PJ,. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6-15.
41. Adams WE, Escudero L,. The aetiology of bronchiectasis: its experimental production and clinical study. Tubercle 1938; 19: 351-364.
42. Croxatto OC, Lanari A,. Pathogenesis of bronchiectasis; experimental study and antomic findings. J Thorac Surg 1954; 27: 514-528.
43. Smaldone GC, Messina MS., Flow limitation, cough, and patterns of aerosol deposition in humans. J Appl Physiol 1985; 59: 515-520.
44. Redding GJ, Kishioka C, Martinez P, Rubin BK,. Physical and transport properties of sputum from children with idiopathic bronchiectasis. Chest 2008; 134: 1129-1134.
45. Wilson R, Roberts D, Cole P,. Effect of bacterial products on human ciliary function in vitro. Thorax 1985; 40: 125-131.
46. Sykes DA, Wilson R, Greenstone M, Currie DC, Steinfort C, Cole PJ,. Deleterious effects of purulent sputum sol on human ciliary function in vitro: at least two factors identified. Thorax 1987; 42: 256-261.
47. Chan TB, Arm JP, Anderson J, Eiser NM,. Pulmonary epithelial permeability in bronchiectasis. Br J Dis Chest 1988; 82: 56-63.
48. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, Brain JD, Accurso FJ, Henson PM,. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002; 109: 661-670.
49. Hodge S, Hodge G, Pizzutto S, Petsky H, Gibson P, Chang A, Upham J,. Reduced macrophage phagocytc host response to NTHi in children with bronchiectasis. Respirology 2014; 19: A86.
50. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA,. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288-295.
51. Fahy JV, Schuster A, Ueki I, Boushey HA, Nadel JA,. Mucus hypersecretion in bronchiectasis. The role of neutrophil proteases. Am Rev Respir Dis 1992; 146: 1430-1433.
52. Daheshia M, Prahl JD, Carmichael JJ, Parrish JS, Seda G,. The immune response and its therapeutic modulation in bronchiectasis. Pulm Med 2012; 2012: 7.
53. Pizzutto SJ, Yerkovich ST, Upham JW, Hales BJ, Thomas WR, Chang AB,. Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-gamma in vitro in response to non-typeable Haemophilus influenzae. PLoS ONE 2014; 9: e104236.
54. Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB,. High pulmonary levels of IL-6 and IL-1β in children with chronic suppurative lung disease are associated with low systemic IFN-γ production in response to non-typeable haemophilus influenzae. PLoS ONE 2015; 10: e0129517.
55. Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T, Xaubet A, Rodriguez-Roisin R, Torres A,. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15-19.
56. Grimwood K,. Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr Respir Rev 2011; 12: 111-118.
57. Zheng L, Lam WK, Tipoe GL, Shum IH, Yan C, Leung R, Sun J, Ooi GC, Tsang KW,. Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo. Eur Respir J 2002; 20: 170-176.
58. Bergin DA, Hurley K, Mehta A, Cox S, Ryan D, O'Neill SJ, Reeves EP, McElvaney NG,. Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J Inflamm Res 2013; 6: 1-11.
59. Boyton RJ, Reynolds CJ, Quigley KJ, Altmann DM,. Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis. Clin Exp Immunol 2013; 171: 117-123.
60. Bals R, Hiemstra PS,. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23: 327-333.
61. Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG,. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62: 211-218.
62. Masekela R, Anderson R, de Boeck K, Vreys M, Steel HC, Olurunju S, Green RJ,. Expression of soluble triggering receptor expressed on myeloid cells-1 in childhood CF and Non-CF bronchiectasis. Pediatr Pulmonol 2015; 50: 333-339.
63. Whitters D, Stockley R,. Immunity and bacterial colonisation in bronchiectasis. Thorax 2012; 67: 1006-1013.
64. Zheng L, Tipoe G, Lam W, Leung R, Ho J, Shum I, Ooi G, Ip M, Tsang K,. Up-regulation of circulating adhesion molecules in bronchiectasis. Eur Respir J 2000; 16: 691-696.
65. Hodge G, Upham JW, Chang AB, Baines KJ, Yerkovich ST, Pizzutto SJ, Hodge S,. Increased peripheral blood pro-inflammatory/cytotoxic lymphocytes in children with bronchiectasis. PLoS ONE 2015; 10: e0133695.
66. Richman-Eisenstat JB, Jorens PG, Hebert CA, Ueki I, Nadel JA,. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993; 264: L413-L418.
67. Angrill J, Agusti C, De Celis R, Filella X, Rano A, Elena M, De La Bellacasa JP, Xaubet A, Torres A,. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628-1632.
68. Guran T, Ersu R, Karadag B, Nuri Akpinar I, Yanikkaya Demirel G, Hekim N, Dagli E,. Association between inflammatory markers in induced sputum and clinical characteristics in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2007; 42: 362-369.
69. Shum DKY, Chan SCH, Ip MSM,. Neutrophil-mediated degradation of lung proteoglycans. Am J Respir Crit Care Med 2000; 162: 1925-1931.
70. Ip M, Lauder IJ, Wong WY, Lam WK, So SY,. Multivariate analysis of factors affecting pulmonary function in bronchiectasis. Respiration 1993; 60: 45-50.
71. Kroegel C, Schüler M, Förster M, Braun R, Grahmann PR,. Evidence for eosinophil activation in bronchiectasis unrelated to cystic fibrosis and bronchopulmonary aspergillosis: discrepancy between blood eosinophil counts and serum eosinophil cationic protein levels. Thorax 1998; 53: 498-500.
72. Fuschillo S, De Felice A, Balzano G,. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008; 31: 396-406.
73. Felton JM, Lucas CD, Rossi AG, Dransfield I,. Eosinophils in the lung-modulating apoptosis and efferocytosis in airway inflammation. Front Immunol 2014; 5: 302.
74. Williams H, O'Reilly RN,. Bronchiectasis in children: its multiple clinical and pathological aspects. Arch Dis Child 1959; 34: 192-201.
75. Hare KM, Grimwood K, Leach AJ, Smith-Vaughan H, Torzillo PJ, Morris PS, Chang AB,. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr 2010; 157: 1001-1005.
76. Edwards EA, Asher MI, Byrnes CA,. Paediatric bronchiectasis in the twenty-first century: experience of a tertiary children's hospital in New Zealand. J Paediatr Child Health 2003; 39: 111-117.
77. Eastham KM, Fall AJ, Mitchell L, Spencer DA,. The need to redefine non-cystic fibrosis bronchiectasis in childhood. Thorax 2004; 59: 324-327.
78. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M, Boucher RC, Wolfgang MC, Elborn JS,. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187: 1118-1126.
79. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, Serisier DJ,. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013; 68: 731-737.
80. Purcell P, Jary H, Perry A, Perry JD, Stewart CJ, Nelson A, Lanyon C, Smith DL, Cummings SP, De Soyza A,. Polymicrobial airway bacterial communities in adult bronchiectasis patients. BMC Microbiol 2014; 14: 130.
81. Chang AB, Grimwood K, Gibson PG, Upham JW,. Protracted bacterial bronchitis (PBB): definition, mechanisms and treatment. Lancet Respir Med 2015; In press.
82. van der Gast CJ, Cuthbertson L, Rogers GB, Pope C, Marsh RL, Redding GJ, Bruce KD, Chang AB, Hoffman LR,. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc 2014; 11: 1039-1048.
83. Wurzel DF, Marchant JM, Clark JE, Masters IB, Yerkovich ST, Upham JW, Chang AB,. Wet cough in children: infective and inflammatory characteristics in broncho-alveolar lavage fluid. Pediatr Pulmonol 2014; 49: 561-568.
84. Alharbi S, Van Caeseele P, Consunji-Araneta R, Zoubeidi T, Fanella S, Souid AK, Alsuwaidi AR,. Epidemiology of severe pediatric adenovirus lower respiratory tract infections in Manitoba, Canada, 1991-2005. BMC Infect Dis 2012; 12: 55.
85. Wurzel DF, Mackay IM, Marchant JM, Wang CY, Yerkovich ST, Upham JW, Smith-Vaughan HC, Petsky HL, Chang AB,. Adenovirus species C is associated with chronic suppurative lung diseases in children. Clin Infect Dis 2014; 59: 34-40.
86. Kieninger E, Singer F, Tapparel C, Alves MP, Latzin P, Tan HL, Bossley C, Casaulta C, Bush A, Davies JC, et al., High rhinovirus burden in lower airways of children with cystic fibrosis. Chest 2013; 143: 782-790.
87. Didierlaurent A, Goulding J, Hussell T,. The impact of successive infections on the lung microenvironment. Immunology 2007; 122: 457-465.
88. Kapur N, Mackay IM, Sloots TP, Masters IB, Chang AB,. Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children. Arch Dis Child 2014; 99: 749-753.
89. Chang AB, Robertson CF, Van Asperen PP, Glasgow NJ, Mellis CM, Masters IB, Teoh L, Tjhung I, Morris PS, Petsky HL, et al., A multicenter study on chronic cough in children: burden and etiologies based on a standardized management pathway. Chest 2012; 142: 943-950.
90. Goyal V, Grimwood K, Marchant J, Masters IB, Chang AB,. Does failed chronic wet cough response to antibiotics predict bronchiectasis ? Arch Dis Child 2014; 99: 522-525.
91. Edwards EA, Metcalfe R, Milne DG, Thompson J, Byrnes CA,. Retrospective review of children presenting with non cystic fibrosis bronchiectasis: HRCT features and clinical relationships. Pediatr Pulmonol 2003; 36: 87-93.
92. Field CE,. Bronchiectasis in childhood: clinical survey of 160 cases. Pediatrics 1949; 4: 21-46.
93. Kapur N, Karadag B,. Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries. Paediatr Respir Rev 2011; 12: 91-96.
94. Field CE,. Bronchiectasis in childhood; aetiology and pathogenesis, including a survey of 272 cases of doubtful irreversible bronchiectasis. Pediatrics 1949; 4: 231-248.
95. Twiss J, Stewart AW, Byrnes CA,. Longitudinal pulmonary function of childhood bronchiectasis and comparison with cystic fibrosis. Thorax 2006; 61: 414-418.
96. Chang AB, Redding GJ, Everard ML,. Chronic wet cough: protracted bronchitis, chronic suppurative lung disease and bronchiectasis. Pediatr Pulmonol 2008; 43: 519-531.
97. Kosar M, Kurt A, Keskin S, Keskin Z, Arslan H,. Evaluation of effects of bronchiectasis on bronchial artery diameter with multidetector computed tomography. Acta Radiol 2014; 55: 171-178.
98. Singleton RJ, Valery PC, Morris P, Byrnes CA, Grimwood K, Redding G, Torzillo PJ, McCallum G, Chikoyak L, Mobberly C, et al., Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatr Pulmonol 2014; 49: 189-200.
99. Doǧru D, Nik-Ain A, Kiper N, Göçmen A, Özçelik U, Yalçin E, Aslan AT,. Bronchiectasis: the consequence of late diagnosis in chronic respiratory symptoms. J Trop Pediatr 2005; 51: 362-365.
100. Zwar NA, Marks GB, Hermiz O, Middleton S, Comino EJ, Hasan I, Vagholkar S, Wilson SF,. Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice. Med J Aust 2011; 195: 168-171.
101. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT,. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-1284.
102. McGuinness G, Naidich DP, Leitman BS, McCauley DI,. Bronchiectasis: CT evaluation. AJR Am J Roentgenol 1993; 160: 253-259.
103. Matsuoka S, Uchiyama K, Shima H, Ueno N, Oish S, Nojiri Y,. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. AJR Am J Roentgenol 2003; 180: 513-518.
104. Kapur N, Masel JP, Watson D, Masters IB, Chang AB,. Bronchoarterial ratio on high-resolution CT scan of the chest in children without pulmonary pathology need to redefine bronchial dilatation. CHEST J 2011; 139: 1445-1450.
105. Hill LE, Ritchie G, Wightman AJ, Hill AT, Murchison JT,. Comparison between conventional interrupted high-resolution CT and volume multidetector CT acquisition in the assessment of bronchiectasis. Br J Radiol 2010; 83: 67-70.
106. Jung KJ, Lee KS, Kim SY, Kim TS, Pyeun YS, Lee JY,. Low-dose, volumetric helical CT: image quality, radiation dose, and usefulness for evaluation of bronchiectasis. Invest Radiol 2000; 35: 557-563.
107. Kim JS, Muller NL, Park CS, Lynch DA, Newman LS, Grenier P, Herold CJ,. Bronchoarterial ratio on thin section CT: comparison between high altitude and sea level. J Comput Assist Tomogr 1997; 21: 306-311.
108. Johkoh T, Muller NL, Colby TV, Ichikado K, Taniguchi H, Kondoh Y, Fujimoto K, Kinoshita M, Arakawa H, Yamada H, et al., Nonspecific interstitial pneumonia: correlation between thin-section CT findings and pathologic subgroups in 55 patients. Radiology 2002; 225: 199-204.
109. Santamaria F, Montella S, Camera L, Palumbo C, Greco L, Boner AL,. Lung structure abnormalities, but normal lung function in pediatric bronchiectasis. Chest 2006; 130: 480-486.
110. Banjar HH,. Clinical profile of Saudi children with bronchiectasis. Indian J Pediatr 2007; 74: 149-152.
111. Kapur N, Masters IB, Chang AB,. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis what influences lung function stability ? CHEST J 2010; 138: 158-164.
112. Lee AL, Button BM, Ellis S, Stirling R, Wilson JW, Holland AE, Denehy L,. Clinical determinants of the 6-minute walk test in bronchiectasis. Respir Med 2009; 103: 780-785.
113. Godfrey S, Springer C, Noviski N, Maayan C, Avital A,. Exercise but not methacholine differentiates asthma from chronic lung disease in children. Thorax 1991; 46: 488-492.
114. Poppelwell L, Chalmers JD,. Defining severity in non-cystic fibrosis bronchiectasis. Expert Rev Respir Med 2014; 8: 249-262.
115. Martinez-Garcia MA, de Gracia J, Vendrell Relat M, Giron RM, Maiz Carro L, de la Rosa Carrillo D, Olveira C,. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014; 43: 1357-1367.
116. Marchant JM, Masel JP, Dickinson FL, Masters IB, Chang AB,. Application of chest high-resolution computer tomography in young children with cystic fibrosis. Pediatr Pulmonol 2001; 31: 24-29.
117. Reid LM,. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950; 5: 233-247.
118. Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, Naidich DP,. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991; 179: 783-788.
119. Nathanson I, Conboy K, Murphy S, Afshani E, Kuhn JP,. Ultrafast computerized tomography of the chest in cystic fibrosis: a new scoring system. Pediatr Pulmonol 1991; 11: 81-86.
120. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM,. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165: 261-267.
121. Webb WR, Muller NL, Naidich DP,. Airway diseases. In: High-resolution CT of the lung. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2009. pp 467-554.
122. Kapur N, Masters IB, Newcombe P, Chang AB,. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest 2012; 141: 1018-1024.
123. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J,. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132: 1565-1572.
124. Chang AB, Bilton D,. Exacerbations in cystic fibrosis: 4-non-cystic fibrosis bronchiectasis. Thorax 2008; 63: 269-276.
125. Murray MP, Turnbull K, MacQuarrie S, Hill AT,. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33: 312-318.
126. Kapur N, Masters IB, Morris PS, Galligan J, Ware R, Chang AB,. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012; 47: 68-75.
127. Redding GJ, Singleton RJ, Valery PC, Williams H, Grimwood K, Morris PS, Torzillo PJ, McCallum GB, Chikoyak L, Holman RC, et al., Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Chest 2014; 146: 762-774.
128. Grimwood K, Bell SC, Chang AB,. Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Rev Anti Infect Ther 2014; 12: 1277-1296.
129. Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR,. Emerging drugs for bronchiectasis: an update. Expert Opin Emerg Drugs 2015; 20: 277-297.
130. Altenburg J, Wortel K, van der Werf TS, Boersma WG,. Non-cystic fibrosis bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by data from a Dutch teaching hospital. Neth J Med 2015; 73: 147-154.
131. Haworth CS, Bilton D, Elborn JS,. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med 2014; 108: 1397-1408.
132. Murray MP, Govan JRW, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT,. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499.
133. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I,. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812-817.
134. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT,. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665.
135. Wurzel D, Marchant JM, Yerkovich ST, Upham JW, Masters IB, Chang AB,. Short courses of antibiotics for children and adults with bronchiectasis. Cochrane Database Syst Rev 2011; 6: CD008695.
136. Ip M, Shum D, Lauder I, Lam WK, So SY,. Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. Respir Med 1993; 87: 449-454.
137. Hill SL, Morrison HM, Burnett D, Stockley RA,. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 1986; 41: 559-565.
138. Miravitlles M, Moragas A, Hernandez S, Bayona C, Llor C,. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment ? Chest 2013; 144: 1571-1577.
139. Chang AB, Grimwood K, Robertson CF, Wilson AC, van Asperen PP, O'Grady KA, Sloots TP, Torzillo PJ, Bailey EJ, McCallum GB, et al., Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. Trials 2012; 13: 156.
140. Tay GT, Reid DW, Bell SC,. Inhaled antibiotics in cystic fibrosis (CF) and non-CF bronchiectasis. Semin Respir Crit Care Med 2015; 36: 267-286.
141. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R,. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39: 39-44.
142. Couch LA,. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001; 120: 114s-117s.
143. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D,. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189: 975-982.
144. Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, et al., Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2: 738-749.
145. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz P, Hampel B,. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41: 1107-1115.
146. Kanoh S, Rubin BK,. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-615.
147. Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R,. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014; 143: 225-245.
148. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, Reynolds PN,. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 139-148.
149. Zhuo G-Y, He Q, Xiang-Lian L, Ya-Nan Y, Si-Te F,. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials. Pulm Pharmacol Ther 2014; 29: 80-88.
150. Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, Masters IB, Diaz A, McCallum GB, Mobberley C, et al., Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis intervention study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 610-620.
151. Ventre K, Randolph AG,. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007; 1: CD000181.
152. Dobson J, Whitley RJ, Pocock S, Monto AS,. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385: 1729-1737.
153. Lee N, Leo YS, Cao B, Chan PK, Kyaw WM, Uyeki TM, Tam WW, Cheung CS, Yung IM, Li H, et al., Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J 2015; 45: 1642-1652.
154. De Clercq E,. Chemotherapy of respiratory syncytial virus infections: the final breakthrough. Int J Antimicrob Agents 2015; 45: 234-237.
155. Lasserson T, Holt K, Evans D, Greenstone M,. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev 2001; 4: CD002163.
156. Kapur N, Bell S, Kolbe J, Chang AB,. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; 1: CD000996.
157. Goyal V, Chang AB,. Combination inhaled corticosteroids and long-acting beta-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014; 6: CD010327.
158. Guran T, Ersu R, Karadag B, Karakoc F, Demirel GY, Hekim N, Dagli E,. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. J Clin Pharm Ther 2008; 33: 603-611.
159. Eaton T, Young P, Zeng I, Kolbe J,. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis 2007; 4: 23-30.
160. Gallon A,. Evaluation of chest percussion in the treatment of patients with copious sputum production. Respir Med 1991; 85: 45-51.
161. Bateman JR, Newman SP, Daunt KM, Sheahan NF, Pavia D, Clarke SW,. Is cough as effective as chest physiotherapy in the removal of excessive tracheobronchial secretions ? Thorax 1981; 36: 683-687.
162. Indinnimeo L, Tancredi G, Barreto M, De Castro G, Zicari AM, Monaco F, Duse M,. Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-year follow-up. Int J Immunopathol Pharmacol 2007; 20: 841-845.
163. Murray MP, Pentland JL, Hill AT,. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34: 1086-1092.
164. Lee AL, Burge A, Holland AE,. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev 2013; 5: CD008351.
165. Lee AL, Hill CJ, Cecins N, Jenkins S, McDonald CF, Burge AT, Rautela L, Stirling RG, Thompson PJ, Holland AE,. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis-a randomised controlled trial. Respir Res 2014; 15: 44.
166. Lee AL, Williamson HC, Lorensini S, Spencer LM,. The effects of oscillating positive expiratory pressure therapy in adults with stable non-cystic fibrosis bronchiectasis: a systematic review. Chron Respir Dis 2015; 12: 36-46.
167. Mandal P, Chalmers JD, Graham C, Harley C,. Atorvastatin as a stable treatment in bronchiectasis: A randomised controlled trial. The lancet respiratory medicine 2014; 2: 455-463.
168. Grimwood K, Kyd JM, Owen SJ, Massa HM, Cripps AW,. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother 2015; 11: 14-20.
169. Teo E, House H, Lockhart K, Purchuri SN, Pushparajah J, Cripps AW, van Driel ML,. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 9: CD010010.
170. O'Grady KA, Grimwood K, Cripps A, Mulholland EK, Morris P, Torzillo PJ, Wood N, Smith-Vaughan H, Revell A, Wilson A, et al., Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial. Trials 2013; 14: 282.
171. Pizzutto SJ, Yerkovich ST, Upham JW, Hales BJ, Thomas WR, Chang AB,. Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease. Vaccine 2015; 33: 321-326.
172. O'Grady KA, Chang AB, Grimwood K,. Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations. Expert Rev Respir Med 2014; 8: 43-55.
173. Kumar A, Lodha R, Kumar P, Kabra SK,. Non-cystic fibrosis bronchiectasis in children: clinical profile, etiology and outcome. Indian Pediatr 2015; 52: 35-37.
174. Ulutas H, Celik MR, Kuzucu A,. Surgical management of upper- and lower-lobe bronchiectasis without middle lobe involvement: is middle lobectomy necessary ? J Pediatr Surg 2012; 47: e25-e28.
175. Ötgün İ, Karnak İ, Tanyel FC, Şenocak ME, Büyükpamukçu N,. Surgical treatment of bronchiectasis in children. J Pediatr Surg 2004; 39: 1532-1536.
176. Balci AE, Balci TA, Özyurtan MO,. Current surgical therapy for bronchiectasis: surgical results and predictive factors in 86 patients. Ann Thorac Surg 2014; 97: 211-217.
177. McCullough AR, Tunney MM, Quittner AL, Elborn JS, Bradley JM, Hughes CM,. Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med 2014; 14: 107.
178. Chang AB, Upham JW, Masters IB, Redding GR, Gibson PG, Marchant JM, Grimwood K,. Protracted bacterial bronchitis: the last decade and the road ahead. Pediatr Pulmonol 2015. [Epub ahead of print].
179. Marchant JM, Masters IB, Taylor SM, Cox NC, Seymour GJ, Chang AB,. Evaluation and outcome of young children with chronic cough. CHEST J 2006; 129: 1132-1141.
180. Marchant JM, Gibson PG, Grissell TV, Timmins NL, Masters IB, Chang AB,. Prospective assessment of protracted bacterial bronchitis: airway inflammation and innate immune activation. Pediatr Pulmonol 2008; 43: 1092-1099.
181. Chang AB, Yerkovich ST, Gibson PG, Anderson-James S, Petsky HL, Carroll ML, Masters IB, Marchant JM, Wurzel D, Upham JW,. Pulmonary innate immunity in children with protracted bacterial bronchitis. J Pediatr 2012; 161: 621-625 e1.
182. Field CE,. Bronchiectasis. Third report on a follow-up study of medical and surgical cases from childhood. Arch Dis Child 1969; 44: 551-561.
183. Chang AB, Marsh RL, Upham JW, Hoffman LR, Smith-Vaughan H, Holt D, Toombs M, Byrnes C, Yerkovich ST, Torzillo PJ, et al., Toward making inroads in reducing the disparity of lung health in Australian indigenous and New Zealand maori children. Front Pediatr 2015; 3: 9.
184. Gaillard EA, Carty H, Heaf D, Smyth RL,. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur J Radiol 2003; 47: 215-220.
185. Haidopoulou K, Calder A, Jones A, Jaffe A, Sonnappa S,. Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function. Pediatr Pulmonol 2009; 44: 669-675.
186. Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR,. Emerging drugs for bronchiectasis. Expert Opin Emerg Drugs 2012; 17: 361-378.
187. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, Etzioni A, Franco JL, Gaspar HB, Holland SM, et al., Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014; 5: 162.
188. Broides A, Yang W, Conley ME,. Genotype/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol 2006; 118: 195-200.
189. Notarangelo LD, Plebani A, Mazzolari E, Soresina A, Bondioni MP,. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. Respiration 2007; 74: 264-275.
190. Dosanjh A,. Chronic pediatric pulmonary disease and primary humoral antibody based immune disease. Respir Med 2011; 105: 511-514.
191. Holland SMMD, DeLeo FRP, Elloumi HZP, Hsu APBA, Uzel GMD, Brodsky NBS, Freeman AFMD, Demidowich ABA, Davis JA, Turner MLMD, et al., STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357: 1608-1619.
192. Milosevic K, Nikolic A, Divac Rankov A, Ljujic M,. Analysis of CFTR gene variants in idiopathic bronchiectasis in Serbian children. Pediatr Allergy Immunol Pulmonol 2013; 26: 93-98.
193. Casals T, De-Gracia J, Gallego M, Dorca J, Rodríguez-Sanchón B, Ramos MD, Giménez J, Cisteró-Bahima A, Olveira C, Estivill X,. Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations ? Clin Genet 2004; 65: 490-495.
194. King PT, Freezer NJ, Holmes PW, Holdsworth SR, Forshaw K, Sart DD,. Role of CFTR mutations in adult bronchiectasis. Thorax 2004; 59: 357-358.
195. Arya AK, Beer HL, Benton J, Lewis-Jones I, Swift AC,. Does Young's syndrome exist ? J Laryngol Otol 2009; 123: 477-481.
196. Maldonado F, Ryu JH,. Yellow nail syndrome. Curr Opin Pulm Med 2009; 15: 371-375.
197. Gupta S, Samra D, Yel L, Agrawal S., T and B cell deficiency associated with yellow nail syndrome. Scand J Immunol 2012; 75: 329-335.
198. Hwang HS, Yi CA, Yoo H, Yang JH,. The prevalence of bronchiectasis in patients with Marfan syndrome. Int J Tuberc Lung Dis 2014; 18: 995-997.
199. Piatti G, De Santi MM, Brogi M, Castorina P, Ambrosetti U,. Emerging ciliopathies: are respiratory cilia compromised in Usher syndrome ? Am J Otolaryngol 2014; 35: 340-346.
200. Karakoc F, Karadag B, Akbenlioglu C, Ersu R, Yildizeli B, Yuksel M, Dagli E,. Foreign body aspiration: what is the outcome ? Pediatr Pulmonol 2002; 34: 30-36.
201. Simon M, Vremaroiu P, Andrei F,. Mounier-Kuhn syndrome. J Bronchology Interv Pulmonol 2014; 21: 145-149.
202. Williams HE, Landau LI, Phelan PD,. Generalized bronchiectasis due to extensive deficiency of bronchial cartilage. Arch Dis Child 1972; 47: 423-428.
203. Strang C,. The fate of children with bronchiectasis. Ann Intern Med 1956; 44: 630-656.
204. Barker DJ, Osmond C,. Childhood respiratory infection and adult chronic bronchitis in England and Wales. Br Med J (Clin Res Ed) 1986; 293: 1271-1275.
205. Shaheen S,. The beginnings of chronic airflow obstruction. Br Med Bull 1997; 53: 58-70.
206. Anwar GA, McDonnell MJ, Worthy SA, Bourke SC, Afolabi G, Lordan J, Corris PA, DeSoyza A, Middleton P, Ward C, et al., Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med 2013; 107: 1001-1007.
207. Ji X-Q, Wang L-X, Lu D-G,. Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol 2014; 20: 13501-13511.
208. Geri G, Dadoun S, Bui T, Del Castillo Pinol N, Paternotte S, Dougados M, Gossec L,. Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases. BMC Infect Dis 2011; 1: 304-304.
209. Puéchal X, Génin E, Bienvenu T, Le Jeunne C, Dusser DJ,. Poor survival in rheumatoid arthritis associated with bronchiectasis: a family-based cohort study. PLoS ONE 2014; 9: e110066.
210. Chalmers JD, McHugh BJ, Doherty C, Smith MP, Govan JR, Kilpatrick DC, Hill AT,. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respir Med 2013; 1: 224-232.
211. Macfarlane JG, Jary H, Hester KL, McAlinden P, Wake J, Small T, Walton KE, Spickett G, De Soyza A,. Low serum mannose-binding lectin level is not associated with disease severity in non-cystic fibrosis bronchiectasis. Innate Immun 2012; 18: 787-792.
212. Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC,. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 2011; 21: 271-282.
213. Kilpatrick DC, Chalmers JD, MacDonald SL, Murray M, Mohammed A, Hart SP, Matsushita M, Hill A,. Stable bronchiectasis is associated with low serum L-ficolin concentrations. Clin Respir J 2009; 3: 29-33.
214. Chalmers JD, Kilpatrick DC, McHugh BJ, Smith MP, Govan JRW, Doherty C, Matsushita M, Hart SP, Sethi T, Hill AT,. T2 single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis. Thorax 2011; 66: A1-A2.
215. Metzger ML, Michelfelder I, Goldacker S, Melkaoui K, Litzman J, Guzman D, Grimbacher B, Salzer U,. Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis. Clin Exp Immunol 2015; 179: 256-264.
216. Hsieh MH, Chou PC, Chou CL, Ho SC, Joa WC, Chen LF, Sheng TF, Lin HC, Wang TY, Chang PJ, et al., Matrix metalloproteinase-1 polymorphism (-1,607G) and disease severity in non-cystic fibrosis bronchiectasis in Taiwan. PLoS ONE 2013; 8: e66265.
217. Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson JM, Flower CD,. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax 1996; 51: 914-918.
218. Westcott JL,. Bronchiectasis. Radiol Clin North Am 1991; 29: 1031-1042.
219. Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, Ooi CC, Yuen KY,. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998; 158: 723-727.
220. Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG,. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62: 211-218.
221. Olveira G, Olveira C, Dorado A, Garcia-Fuentes E, Rubio E, Tinahones F, Soriguer F, Murri M., Cellular and plasma oxidative stress biomarkers are raised in adults with bronchiectasis. Clin Nutr 2013; 32: 112-117.
222. Ergan Arsava B, Cöplü L,. Does airway colonization cause systemic inflammation in bronchiectasis ? Tüberküloz ve toraks 2011; 59: 340-347.
223. Loukides S, Bouros D, Papatheodorou G, Lachanis S, Panagou P, Siafakas NM,. Exhaled H2O2 in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest 2002; 121: 81-87.
224. Quint JK, Donaldson GC, Goldring JJP, Baghai-Ravary R, Hurst JR, Wedzicha JA,. Serum IP-10 as a biomarker of human Rhinovirus infection at exacerbation of COPD. CHEST J 2010; 137: 812-822.
225. Baines KJ, Upham JW, Yerkovich ST, Chang AB, Marchant JM, Carroll M, Simpson JL, Gibson PG,. Mediators of neutrophil function in children with protracted bacterial bronchitis. Chest 2014; 146: 1013-1020.